DKN-01 + paclitaxel

**DKN-01 + paclitaxel** is an experimental combination therapy being tested for advanced cancer indications, principally gynecologic malignancies such as endometrioid endometrial cancer and ovarian cancer[1][5][7]. DKN-01 is an investigational humanized IgG4 monoclonal antibody that targets **Dickkopf-1 (DKK1)**, an inhibitor of Wnt signaling and a key player in tumor growth and immune evasion[3][5]. Paclitaxel is an approved chemotherapeutic agent (a taxane class small molecule) that stabilizes microtubules and inhibits cell division, leading to mitotic arrest and apoptosis[2][4][6][8]. In combination, DKN-01 is intended to block tumor-promoting DKK1/Wnt pathway activity, while paclitaxel directly cytotoxically targets dividing cancer cells by stabilizing tubulin. The combination is typically administered intravenously and investigated for safety and antitumor activity in phase I/II clinical trials, with DKN-01 dosing ranging from 150 mg to 300 mg IV, and paclitaxel given weekly IV[1][5][7].

Brand names

AbraxaneNaveruclifPazenir

Other names

DKN-01 + paclitaxelDKN01 + paclitaxel